Breaking News Instant updates and real-time market news.

VTGN

VistaGen Therapeutics

$1.72

-0.03 (-1.71%)

08:48
02/13/19
02/13
08:48
02/13/19
08:48

VistaGen Therapeutics receives notice of allowance from USPTO for PH10 patent

VistaGen Therapeutics announced that the U.S. Patent and Trademark Office, or USPTO, has provided a notice of allowance for a patent related to methods of treating depression with PH10, VistaGen's investigational new generation CNS nasal spray in Phase 2 development for major depressive disorder. Counterpart foreign patents have already issued in Europe, Japan and several other countries. In a small exploratory Phase 2a clinical study, at microgram doses, PH10 nasal spray was observed to have rapid-onset antidepressant effects, without systemic exposure, psychological side effects or safety concerns.

VTGN VistaGen Therapeutics
$1.72

-0.03 (-1.71%)

05/24/18
OPCO
05/24/18
INITIATION
Target $6
OPCO
Outperform
VistaGen Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Jay Olson started VistaGen Therapeutics with an Outperform rating and $6 price target. The company is "underappreciated and undervalued, with a novel, potentially best-in-class, rapid acting oral antidepressant," Olson tells investors in a research note. He believes AV-101 may offer ketamine-like efficacy without the side effects or inconvenience and that trial readouts by mid-2019 could unlock "substantial shareholder value."
05/25/18
05/25/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Enanta (ENTA) initiated with an Outperform at Oppenheimer. 2. VistaGen Therapeutics (VTGN) initiated with an Outperform at Oppenheimer. 3. Engility (EGL) initiated with a Buy at Stifel. 4. ManTech (MANT) initiated with a Hold at Stifel. 5. SAIC (SAIC) initiated with a Hold at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, Reference Link
06/27/18
MAXM
06/27/18
INITIATION
Target $6
MAXM
Buy
VistaGen Therapeutics initiated with a Buy at Maxim
Maxim initiated VistaGen Therapeutics with a Buy and $6 price target.
06/27/18
MAXM
06/27/18
INITIATION
Target $6
MAXM
Buy
VistaGen Therapeutics initiated with a Buy at Maxim
As reported earlier, Maxim analyst Caroline Palomeque initiated VistaGen Therapeutics (VTGN) with a Buy rating and a price target of $6 based on its lead drug candidate, AV-101, an oral antidepressant targeting modulation of the NMDA receptor which is an emerging new class of antidepressants. The analyst notes that while Johnson & Johnson (JNJ) and Allergan (AGN) have first mover advantage in the NMDA class, their respective intranasal and IV in-office administration differentiates AV-101 as an oral at-home alternative. Palomeque notes the company's is progressing with its clinical development, as AV-101 undergoes phase 2 studies in treatment resistant major depressive disorder and adjunctive therapy in frontline failed patients, with data expected in the second half of this year and first half of 2019 respectively.

TODAY'S FREE FLY STORIES

CZR

Caesars

$9.42

-0.21 (-2.18%)

18:06
02/21/19
02/21
18:06
02/21/19
18:06
Hot Stocks
Breaking Hot Stocks news story on Caesars »

Caesars says will not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

LNT

Alliant Energy

$45.63

0.45 (1.00%)

18:03
02/21/19
02/21
18:03
02/21/19
18:03
Earnings
Breaking Earnings news story on Alliant Energy »

Alliant Energy sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

LNT

Alliant Energy

$45.63

0.45 (1.00%)

18:02
02/21/19
02/21
18:02
02/21/19
18:02
Earnings
Alliant Energy reports Q4 EPS 36c, conseensus 35c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

BVN

Buenaventura

$16.53

-0.37 (-2.19%)

17:59
02/21/19
02/21
17:59
02/21/19
17:59
Earnings
Buenaventura reports Q4 EPS (29c), consensus 5c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 12

    Mar

  • 12

    Mar

KHC

Kraft Heinz

$48.19

-0.05 (-0.10%)

17:58
02/21/19
02/21
17:58
02/21/19
17:58
Hot Stocks
Kraft Heinz says expects to face profit headwinds in 2019 »

Says: Expects EBITDA down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

GABC

German American Bancorp

$31.59

(0.00%)

, CZFC

Citizens First

$23.30

1.87 (8.73%)

17:56
02/21/19
02/21
17:56
02/21/19
17:56
Hot Stocks
German American, Citizens First announce merger pact »

German American Bancorp,…

GABC

German American Bancorp

$31.59

(0.00%)

CZFC

Citizens First

$23.30

1.87 (8.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$291.18

-11.33 (-3.75%)

17:56
02/21/19
02/21
17:56
02/21/19
17:56
Periodicals
Lucid Motors is 'working' on an all electric SUV, Verge says »

Electric vehicle startup…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 18

    Mar

  • 19

    Mar

CZR

Caesars

$9.42

-0.21 (-2.18%)

17:54
02/21/19
02/21
17:54
02/21/19
17:54
Hot Stocks
Caesars sees FY19 same-store capex $375M-$450M »

Sees FY19 development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

PBA

Pembina Pipeline

$36.44

-0.235 (-0.64%)

17:54
02/21/19
02/21
17:54
02/21/19
17:54
Earnings
Pembina Pipeline reports Q4 EPS C$0.66 vs C$0.83 last year »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

KHC

Kraft Heinz

$48.19

-0.05 (-0.10%)

17:53
02/21/19
02/21
17:53
02/21/19
17:53
Hot Stocks
Kraft Heinz continues to fall, now down 16.5% to $40.25 »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

CZR

Caesars

$9.42

-0.21 (-2.18%)

17:52
02/21/19
02/21
17:52
02/21/19
17:52
Hot Stocks
Caesars says in discussions with Carl Icahn after his disclosed stake »

Comments from Q4 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

HRS

Harris

$164.55

-0.62 (-0.38%)

17:48
02/21/19
02/21
17:48
02/21/19
17:48
Hot Stocks
Harris awarded $168.8M Navy contract modification »

Harris has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KHC

Kraft Heinz

$48.19

-0.05 (-0.10%)

17:45
02/21/19
02/21
17:45
02/21/19
17:45
Hot Stocks
Kraft Heinz to cut quarterly dividend to 40c from 62.5c per share »

Says: Higher supply chain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

HON

Honeywell

$152.60

-1.2 (-0.78%)

17:43
02/21/19
02/21
17:43
02/21/19
17:43
Hot Stocks
Honeywell awarded not-to-exceed $150M Air Force contract for ATTAM Phase 1 »

Honeywell has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

BA

Boeing

$417.48

-4.13 (-0.98%)

17:40
02/21/19
02/21
17:40
02/21/19
17:40
Hot Stocks
Tapestry awarded not-to-exceed $259M Air Force contract for WPS »

Tapestry Solutions, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

  • 28

    May

INFN

Infinera

$4.87

-0.02 (-0.41%)

17:39
02/21/19
02/21
17:39
02/21/19
17:39
Earnings
Infinera sees Q1 EPS (27c) plus/minus 2c, consensus (19c) »

Sees Q1 GAAP revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

CRON

Cronos Group

$22.45

0.22 (0.99%)

, MO

Altria Group

$50.38

-0.14 (-0.28%)

17:37
02/21/19
02/21
17:37
02/21/19
17:37
Hot Stocks
Cronos Group shareholders approve C$2.4B investment from Altria Group »

Cronos Group (CRON)…

CRON

Cronos Group

$22.45

0.22 (0.99%)

MO

Altria Group

$50.38

-0.14 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

BAH

Booz Allen

$53.64

-0.105 (-0.20%)

, GD

General Dynamics

$171.66

-2.78 (-1.59%)

17:36
02/21/19
02/21
17:36
02/21/19
17:36
Hot Stocks
Booz Allen, General Dynamics, Leidos and SAIC awarded DTRA contracts »

Booz Allen (BAH), General…

BAH

Booz Allen

$53.64

-0.105 (-0.20%)

GD

General Dynamics

$171.66

-2.78 (-1.59%)

LDOS

Leidos

$62.87

1.175 (1.90%)

SAIC

SAIC

$75.73

-0.75 (-0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

INFN

Infinera

$4.87

-0.02 (-0.41%)

17:35
02/21/19
02/21
17:35
02/21/19
17:35
Earnings
Infinera reports Q4 EPS (25c), consensus (27c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

ECIFF

EDF

$0.00

(0.00%)

17:33
02/21/19
02/21
17:33
02/21/19
17:33
Downgrade
EDF rating change  »

EDF downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEE

Lee Enterprises

$2.69

0.075 (2.87%)

17:32
02/21/19
02/21
17:32
02/21/19
17:32
Hot Stocks
Lee Enterprises' TownNews acquires CMS business from GTxcel »

Lee Enterprises announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CENX

Century Aluminum

$9.30

0.12 (1.31%)

17:31
02/21/19
02/21
17:31
02/21/19
17:31
Earnings
Century Aluminum reports Q4 EPS (43c), consensus (53c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

EXEL

Exelixis

$21.22

(0.00%)

17:30
02/21/19
02/21
17:30
02/21/19
17:30
Initiation
Exelixis initiated  »

Exelixis initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPSN

Epsilon Energy

$0.00

(0.00%)

17:30
02/21/19
02/21
17:30
02/21/19
17:30
Hot Stocks
Epsilon Energy sees 2019 production growth of 27%-33% y/y »

The company anticipates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSRM

SSR Mining

$14.13

0.245 (1.76%)

17:29
02/21/19
02/21
17:29
02/21/19
17:29
Earnings
SSR Mining sees FY19 gold production 395,000 equivalent ounces »

At the Marigold mine,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.